Passage BIO, Inc. — Director's Dealing 2021

Mar 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2021-03-22

Reporting Person: Salinas Eliseo Oreste (Chief Res. & Develop Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-22	Employee Stock Option (Right to buy)	$18.85	A	275000	Acquired	2031-03-22	Common Stock (275000)	Direct
2021-03-22	Restricted Stock Unit (RSU)	$	A	40000	Acquired		Common Stock (40000)	Direct
2021-03-22	Restricted Stock Unit (RSU)	$	A	60000	Acquired		Common Stock (60000)	Direct

Footnotes

F1: The option vests as to 25% of the total shares on March 22, 2022, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on March 22, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3: The RSUs shall vest as to 33.33% of the total shares each on June 15, 2021, September 15, 2021 and December 15, 2021, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F4: 1/4 of the RSUs will vest on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.